Overview

A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants

Status:
Completed

Trial end date:
2023-09-20

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the effect of a cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and CYP3A4 inducer (carbamazepine) on the single dose pharmacokinetics (PK) of DC-806 coadministered with itraconazole or carbamazepine in healthy male and female participants.

Phase:

Phase 1

Details

Lead Sponsor:

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Treatments:

Carbamazepine
Itraconazole